
I'm a celebrity doctor & never judge mums for using Mounjaro – trying to diet & exercise on zero sleep is overwhelming
Click to share on Facebook (Opens in new window)
A CELEBRITY doctor has defended sleep-deprived mums who are turning to fat jabs to lose weight.
Dr Punam Krishan, who starred on Strictly Come Dancing with Gorka Marquez, took to social media to give her opinion on the flab-busting medication.
4
Dr Punam Krishan has defended mums who use Mounjaro
4
Dr Punam appeared on Strictly Come Dancing
Credit: PA
About half a million Brits use weight loss drugs - and the number is expected to double in the next year.
Of those, Mounjaro is regarded by some as the King Kong of fat jabs.
Dr Punam, 42, said: "There is a lot of noise right now about weight loss jabs. It's everywhere on social media, in magazines, in WhatsApp groups and I understand and I get the curiosity.
"But behind every decision to start one of these medications is usually a much bigger story which your GP gets to hear and these are stories that deserve understanding and compassion, not judgement, criticism or to become the subject of gossip."
The telly doc, a resident on BBC Morning Live and Radio Scotland added: "I see women all the time, especially mums in their 30s, 40s and 50s who have spent years trying everything to manage their weight.
"They've dieted, exercised, cut out carbs, counted calories, tried intuitive eating and still felt stuck.
"Then you add in the poor sleep, the high stress, the hormonal chaos of perimenopause, the mental load of family life, a demanding job like oh my gosh. It's no wonder so many people feel completely overwhelmed by it all.
"Now for some, the decision to try something like Mounjaro is about their weight affecting their health. So things like blood pressure, diabetes risk, heart disease, sleep apnea or joint pain.
"For others it's about confidence, it's wanting to feel more like themselves again. but whatever the reason, it is personal and it deserves support, not shame."
Mounjaro works by suppressing your appetite, making people feel fuller for longer.
I've lost nearly 6 stone in 9 months on fat jabs - trolls call me 'lazy' & say it's the 'easy way out' but I don't care
The injections are licensed for patients with type 2 diabetes and to assist those who are clinically obese (with a Body Mass Index of 30 or over).
One jab is administered each week but the duration is dependent on someone's weight.
The drugs can be prescribed by a practitioner - such as a doctor, nurse or a pharmacist-independent prescriber.
But increasingly, many have been buying them through online pharmacies without sufficient checks or information about side effects including headaches and even pancreatitis.
Dr Punam told her 119,000 Instagram followers: "Sadly we are seeing a lot of misuse and there is loads and loads of misinformation out there. That really worries me as a doctor.
"These are serious medications and I believe that people deserve proper information before jumping in to take them."
4
Dr Punam insisted Mounjaro is 'not a magic fix'
Credit: Getty
4
But the practicing GP says she will never judge anybody for using the weight loss jabs
Credit: Getty
And the practicing GP — who has son Aanish and daughter Ellora to Tory MSP hubby Dr Sandesh Gulhane — insisted that weight loss jabs are "not a magic fix".
She added: "Long-term weight management still depends on the basics.
"So nourishing food, movement that protects your muscle, your sleep, your stress levels, cutting back on alcohol and just looking at underlying health issues that may be contributing like thyroid function or perimenopause.
"If the root cause isn't addressed, the weight will often just come back when you stop the medication.
"And one more thing that I really really want to say clearly is if you are on one of these jabs then please tell your GP.
"I know some people feel embarrassed or a bit worried. They think that we might judge them but that's just not the case. We're not here to tell you off. We're here to keep you safe.
"Don't ever ignore new or persisting symptoms. It's always better to get things checked out.
"The one tip that I always give my patients is to have a quick look at your pee. The colour of your urine is important.
"If it is clear or light straw coloured, great, but if it is looking dark yellow and concentrated, you probably need to drink more.
"I'm also seeing a bit of muscle loss in some people and that is not something that we want. So if you're not eating enough or you're not moving much, then your body starts to break down muscle alongside the fat.
"You don't need to go daft at the gym, but even just doing some body weight strength training exercises two to three times a week can really help to protect your muscle and keeps your metabolism ticking over."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mirror
an hour ago
- Daily Mirror
Weight loss pill that helped patients shift 12% of body mass may soon be on NHS
A weight-loss tablet, which could be a cheaper and easier alternative to jabs and has seen patients during a trial lose up to almost 2st, could soon be available on the NHS A powerful new generation of weight-loss pill that could provide hope for millions of patients is set to be considered by regulators for NHS approval. A trial found overweight people taking the medication lost up to almost 2st – or 12% of their body weight – after 18 months. The maker, US firm Lilly, said it will seek the go-ahead by regulators for the drug orforglipron. It could be a cheaper and easier alternative to weight-loss jabs, which have to be refrigerated. The daily tablet is a GLP-1 agonist, which can cut appetite. Like jabs, the pill mimics the effects of hormones that make us feel full. Lilly also makes weight-loss jab Mounjaro. It comes after the NHS warned mouth symptom could be life-shortening disease. Kenneth Custer, of Lilly, said: 'We're working to transform obesity care with a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments. 'We are planning to submit orforglipron for regulatory review by year-end.' It will need to be approved as safe by the Medicines and Healthcare products Regulatory Agency before the National Institute for Health and Care Excellence decides if it is cost-effective for the NHS. The Mirror understands guidance is expected next year on whether it will be available on the health service. The study found 60% of people on the highest dose of orforglipron lost at least 10% of their body weight. While 40% of people shed at least 15% of their body weight. The study of 3,127 overweight adults also found benefits such as better cholesterol. Lilly said the safety profile of the tablet is similar to other GLP-1 drugs, with gastrointestinal issues the most common side effect. Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University, said: 'These early results on the effectiveness of orforglipron in promoting clinically significant weight loss are a positive step forward in the development of this class of drugs. 'Their effects on weight loss are not as profound as that seen in [jabs]. 'Nevertheless, that this medication is an oral form, rather than injectable, will likely be seen as more tolerable for many. Manufacturing costs are also anticipated to be significantly lower.' An estimated 1.5 million people in the UK use weight-loss medication, most privately. Mounjaro was due to be rolled out across the NHS in England from June 23 for those with the highest clinical need, but a probe found only eight of 42 NHS integrated care boards are providing it at present. Nearly half of boards say they will cap the number they treat due to lack of funding. NHS England says the plan is for jabs to bemore widely available. Figures suggest about 29% of adults are obese. Another new study has found GLP-1s may have other benefits such as improving Alzheimer's and liver disease.

Western Telegraph
3 hours ago
- Western Telegraph
Mounjaro hair loss searches have more than doubled in a year
Online searches for 'Mounjaro hair loss' have more than doubled in the past year, increasing by 143% . The condition, known as telogen effluvium, is a temporary form of hair loss linked to physical stress. Hair regrowth typically begins three to six months after weight loss stabilises. 'Hair loss on Mounjaro isn't typically due to the medication itself, but rather the metabolic changes that come with sudden weight loss," says Jason Murphy, Head of Pharmacy at Chemist4U. "When people lose a significant amount of weight quickly, typically 10-20% of their body weight in just a few months, it puts the body under stress. "That stress, combined with changes in diet and hormones, can trigger telogen effluvium.' Telogen effluvium causes hair follicles to shift prematurely into their resting phase. Normally, most hair is actively growing, with only a small percentage resting. But when the body is under stress, a larger proportion switches to resting, leading to increased shedding two to three months later. 'This is your body's way of conserving energy during a period of change,' he says. 'Hair growth isn't essential for survival, so the body temporarily redirects energy elsewhere. It's understandably upsetting for patients, but it's actually a protective response.' Recommended reading: How to minimise hair loss during Mounjaro treatment While hair shedding on Mounjaro is often temporary, it can still be distressing for those experiencing it. Fortunately, there are simple, science-backed steps that you can take to protect your hair. 1. Follow proper dose titration "Your doctor or pharmacist will monitor your progress while you're taking Mounjaro," says Jason, an expert in weight loss injections. "Follow your prescribed schedule carefully, this is sometimes called titration, and don't try to increase your dose or lose weight too quickly. Aiming for around 1 to 2 pounds a week is much gentler on the body and can reduce how much hair you shed." 2. Prioritise protein and balanced nutrition Protein is essential for growing healthy hair because it's the building block of new hair cells. It also helps your body produce the enzymes and hormones needed to support hair growth from the inside out. If your diet lacks essential nutrients, a daily multivitamin can help fill the gaps. Look for products with biotin, iron and zinc, as these play an important role in nourishing your hair follicles and scalp. 3. Practice gentle hair care Avoid harsh brushing, heat styling or tight hairstyles like ponytails and braids as these can put extra stress on your hair. Use a mild shampoo that won't strip your scalp of its natural oils. Over-washing can lead to irritation, so washing two to three times a week is often enough unless you have very oily hair. 4. Support scalp health Scalp massage can stimulate blood circulation to the scalp, improving its overall health and promoting hair regrowth. Using a massage brush or your fingertips to massage your scalp can also help distribute haircare products more evenly and make them more effective. If your hair feels dry or damaged, natural remedies like rosemary oil or black tea can help repair it at home. 5. Prioritise sleep and stress management Stress is a well-known trigger for hair loss. To support both your mental health and hair health, build in time for rest, sleep and activities that help you manage stress, whether it's regular exercise, mindfulness or simply taking time out for yourself. Most adults should aim for 7 to 9 hours sleep per night. This is particularly important for those experiencing hair loss, as quality sleep supports the regulation of growth hormone and tissue repair. 6. Explore topical treatments "If you notice hair shedding while taking Mounjaro, speak to your GP or pharmacist about topical Minoxidil (Regaine for Men or Regaine for Women)," says Jason. "Minoxidil encourages blood flow to your scalp and hair follicles. This can help nutrients and oxygen flow into your hair so it grows back stronger."


Powys County Times
6 hours ago
- Powys County Times
High demand expected for new daily weight loss pill
A trial assessing a new daily pill for weight loss has shown that people taking the drug can shed kilos in weeks, potentially offering people with obesity a new and convenient alternative to jabs. Pharmaceutical company Eli Lilly said it expects substantial demand when the new pill is launched. Lilly said it will seek approval by international regulators as it published the results of a large study into orforglipron. The new pill is a GLP-1 agonist, a type of medication which helps lower blood sugar levels, slows the digestion of food and can reduce appetite. The manufacturer also makes Mounjaro, dubbed the King Kong of weight loss jabs. Weight loss jabs have been hailed as transformative by health leaders. But injections come with additional work for over-stretched health services so tablet forms of medication, which are expected to be cheaper and easier to use, may offer a new hope for the millions of people looking to lose weight. The new study data on orforglipron showed that people taking the drug lost an average of 12.3 kilograms while taking the drug for 72 weeks compared with those not taking the drug. Three in five (60%) of people taking the highest dose of orforglipron lost at least 10% of their body weight, while 40% lost at least 15% of their body weight, according to the study, which is to be presented to the European Association for the Study of Diabetes (EASD) Annual Meeting 2025. A once-a-day pill to treat obesity could be a game-changer. Today we announced positive results of a late-stage clinical trial studying a once-daily oral medicine for obesity. Read more: — Eli Lilly and Company (@EliLillyandCo) August 7, 2025 In addition to weight loss the people in the study also showed other health benefits, including improvements in cholesterol, blood pressure and heart disease risk. Experts highlighted how the tablet did not appear to yield the same benefits as some weight loss jabs, but said they will be more 'tolerable' for many patients. Lilly said the safety profile of the tablet is similar to other GLP-1 drugs, with gastrointestinal issues the most commonly reported side effect. The pill was assessed in a study of 3,127 adults who were obese or overweight, with a weight-related medical problem and without diabetes. 'With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments,' said Lilly's Kenneth Custer. 'With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need.' Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University, said: 'These preliminary results on the effectiveness of orforglipron in promoting clinically significant weight loss are a positive step forward in the development of this class of drugs. 'It should be noted that their effects on weight loss are not as profound as that seen in injectable GLP-1 receptor agonists, such as Wegovy, with a lower percentage weight loss and fewer people achieving 10% weight loss at the highest dose. 'Nevertheless, that this medication is an oral form, rather than injectable, will likely be seen as more tolerable for many patients. 'The manufacturing costs are also anticipated to be significantly lower than injectable drugs, meaning these medications may be more equitable in their availability. 'It should be noted that these are preliminary, non-peer reviewed results and we will need to see the full trial methodology and data before a more comprehensive analysis can be undertaken.' It comes as a separate study highlighted the potential other benefits of using GLP-1s, also known as glucagon-like peptide 1 receptor-agonists. They were initially developed as a treatment for people with type 2 diabetes and are now widely used to treat obesity and help people lose weight. The separate paper, from McGill University and the Lady Davis Institute for Medical Research at the Jewish General Hospital in Canada, examined the benefits of these drugs beyond weight loss by looking at trials which had assessed the drugs in other areas of medicine. Writing in the journal eClinicalMedicine, experts said GLP-1s may also play a role in improving liver disease; sleep apnoea; arthritis of the knee; polycystic ovary syndrome; Parkinson's disease; Alzheimer's disease and substance misuse. But they also highlighted potential safety issues linked to the drugs including potential issues with the pancreas and gall bladder. 'The therapeutic landscape for obesity and related metabolic conditions has evolved substantially with the emergence of GLP-1 RAs,' they wrote. 'These agents now play a central role not only in weight management and diabetes care but are also being investigated in a growing number of conditions, including cardiovascular, renal, hepatic, neurologic, and substance use disorders. 'As their indications expand, so must our understanding of long-term efficacy, safety, and patient-centred treatment strategies.'